POLITICSWhat to expect from Trump's speech on drug prices on FridayBy Bill MeagherMay 10, 2018 2:43 PM EDT
MERGERS AND ACQUISITIONSThese Are the Biggest Winners and Losers in Activist Investing This YearBy Ronald OrolDec 11, 2017 7:04 AM EST
REGULATIONOpioid Makers Buffeted by Trump's Declaration of Addiction CrisisBy William McConnellAug 11, 2017 1:20 PM EDT
HEALTHBiotech Movers: FibroGen Leaps on Results for Pulmonary Fibrosis StudyBy Armie Margaret LeeAug 8, 2017 9:29 AM EDT
HEALTHDepomed, Insys Shares Down After FDA Decision on Endo's Opana ERBy Melissa AngellJun 9, 2017 5:20 PM EDT
MERGERS AND ACQUISITIONSBeefing Up Nucynta Franchise, Not M&A Is Depomed's Focus NowBy William McConnellMay 10, 2017 7:38 PM EDT
STOCKSBiotech Movers: Depomed Shares Tank After Earnings Get Even WorseBy William McConnellMay 10, 2017 9:34 AM EDT
STOCKSAnalysts' Actions -- Allergan, Coach, General Dynamics, Occidental and MoreBy TheStreet StaffMay 10, 2017 9:29 AM EDT
POLITICSOpioid Makers Fall After FDA Pick Gottlieb Says America's Drug Addiction Is Out of ControlBy William McConnellApr 5, 2017 5:00 PM EDT
HEALTHBiotech Premarket Movers: Sage Therapeutics, Depomed, NantKwestBy Armie Margaret LeeMar 31, 2017 9:28 AM EDT
HEALTHBiotech Premarket Movers: Vertex, Sangamo, DepomedBy Armie Margaret LeeMar 29, 2017 9:31 AM EDT
MERGERS AND ACQUISITIONSDepomed switches out CEO and board in making peace with activist StarboardBy Bill MeagherMar 29, 2017 7:01 AM EDT
STOCKSSenator McCaskill Launching Investigation Into Opioid DrugmakersBy Amanda SchiavoMar 28, 2017 1:30 PM EDT
MERGERS AND ACQUISITIONSA Deal is Imminent For Depomed, CFO SaysBy Alicia McElhaneyMar 23, 2017 7:07 PM EDT
STOCKSPain med company Depomed reports adjusted earnings of $1.15 per shareBy Bill MeagherFeb 21, 2017 8:34 PM EST
MERGERS AND ACQUISITIONSPerrigo settles with activist investor StarboardBy Armie Margaret LeeFeb 7, 2017 1:39 PM EST
STOCKSBiotech stock mailbag: Trump, Aurinia, Immunomedics, CellceutixBy Adam FeuersteinJan 27, 2017 8:13 AM EST
FUTURESDow's march to 20,000 hits another snag as crude settles at two-week lowBy Keris Alison LahiffJan 3, 2017 4:06 PM EST
FUTURESDow's attempt at 20,000 fades as crude reverses courseBy Keris Alison LahiffJan 3, 2017 3:09 PM EST
FUTURESStocks ease off highs as Dow 20,000 remains a challengeBy Keris Alison LahiffJan 3, 2017 11:07 AM EST
FUTURESStock futures rise ahead of first trading day of 2017By Keris Alison LahiffJan 3, 2017 8:42 AM EST
MERGERS AND ACQUISITIONSRanking the activists for proxy season 2016By Ronald OrolDec 1, 2016 8:02 AM EST
